# Mettler Toledo International Inc/: overview

MTD · NYSE · CIK 1037646 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mtd.md) · [Financials](/companies/mtd/financials.md) · [Filings](/companies/mtd/filings.md) · [Insiders](/companies/mtd/insiders.md)

Latest reported revenue: [$1.03bn](/filings/0001037646-26-000051.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 31, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001037646-26-000051).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [955](/filings/0001037646-25-000058.md) | [1,045 d](/filings/0001037646-26-000011.md) | [884](/filings/0001037646-26-000021.md) | [983](/filings/0001037646-26-000051.md) | [1,030](/filings/0001037646-25-000058.md) | [1,130 d](/filings/0001037646-26-000011.md) | [947](/filings/0001037646-26-000021.md) | [1,027](/filings/0001037646-26-000051.md) |
| Gross margin | % | [60.0%](/filings/0001037646-25-000058.md) | [61.2% d](/filings/0001037646-26-000011.md) | [59.5%](/filings/0001037646-26-000021.md) | [59.0%](/filings/0001037646-26-000051.md) | [59.2%](/filings/0001037646-25-000058.md) | [59.8% d](/filings/0001037646-26-000011.md) | [58.7%](/filings/0001037646-26-000021.md) | [63.3%](/filings/0001037646-26-000051.md) |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [22.2%](/filings/0001037646-25-000058.md) | [24.1% d](/filings/0001037646-26-000011.md) | [18.5%](/filings/0001037646-26-000051.md) | [20.6%](/filings/0001037646-26-000051.md) | [21.1%](/filings/0001037646-25-000058.md) | [25.3% d](/filings/0001037646-26-000011.md) | [17.9%](/filings/0001037646-26-000051.md) | [22.7%](/filings/0001037646-26-000051.md) |
| Diluted EPS | $ per share | [9.96](/filings/0001037646-25-000058.md) | not reported | [7.81](/filings/0001037646-26-000021.md) | [9.76](/filings/0001037646-26-000051.md) | [10.57](/filings/0001037646-25-000058.md) | not reported | [8.33](/filings/0001037646-26-000021.md) | [11.55](/filings/0001037646-26-000051.md) |
| Free cash flow | $m | [233 d](/filings/0001037646-25-000058.md) | [225 d](/filings/0001037646-26-000011.md) | [177](/filings/0001037646-26-000021.md) | [212 d](/filings/0001037646-26-000051.md) | [275 d](/filings/0001037646-25-000058.md) | [184 d](/filings/0001037646-26-000011.md) | [122](/filings/0001037646-26-000021.md) | [283 d](/filings/0001037646-26-000051.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,718](/filings/0001037646-24-000007.md) | [3,920](/filings/0001037646-25-000012.md) | [3,788](/filings/0001037646-26-000011.md) | [3,872](/filings/0001037646-26-000011.md) | [4,026](/filings/0001037646-26-000011.md) |
| Gross margin | % | [58.4%](/filings/0001037646-24-000007.md) | [58.9%](/filings/0001037646-25-000012.md) | [59.2%](/filings/0001037646-26-000011.md) | [60.1%](/filings/0001037646-26-000011.md) | [59.4%](/filings/0001037646-26-000011.md) |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [20.7%](/filings/0001037646-24-000007.md) | [22.3%](/filings/0001037646-25-000012.md) | [20.8%](/filings/0001037646-26-000011.md) | [22.3%](/filings/0001037646-26-000011.md) | [21.6%](/filings/0001037646-26-000011.md) |
| Diluted EPS | $ per share | [32.78](/filings/0001037646-24-000007.md) | [38.41](/filings/0001037646-25-000012.md) | [35.90](/filings/0001037646-26-000011.md) | [40.48](/filings/0001037646-26-000011.md) | [42.05](/filings/0001037646-26-000011.md) |
| Free cash flow | $m | [801](/filings/0001037646-24-000007.md) | [738](/filings/0001037646-25-000012.md) | [861](/filings/0001037646-26-000011.md) | [864](/filings/0001037646-26-000011.md) | [849](/filings/0001037646-26-000011.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mtd/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.40bn | 1,882,344 |  | Added +111,342 |
| [Capital International Investors](/funds/1562230.md) | 2026-06-30 | $1.94bn | 1,521,543 |  | Added +440,772 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.69bn | 1,319,636 |  | Reduced −2,218 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.29bn | 1,010,490 |  | Added +14,406 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.22bn | 951,679 |  | Added +9,144 |
| [ALLIANCEBERNSTEIN L.P.](/funds/1109448.md) | 2026-06-30 | $856.5m | 679,101 |  | Reduced −78,007 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $780.5m | 612,153 |  | Added +6,414 |
| [Bank of New York Mellon Corp](/funds/1390777.md) | 2026-06-30 | $762.6m | 596,906 |  | Reduced −106,573 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $594.3m | 465,226 |  | Reduced −22,855 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $586.5m | 459,064 |  | Added +413,547 |

## Recent filings

[All 1,309 filings](/companies/mtd/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-03 | 16:48 ET | [8-K](/filings/0001037646-26-000054.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001037646-26-000054 |
| 2026-07-31 | 13:17 ET | [10-Q](/filings/0001037646-26-000051.md) | Quarterly report, period 2026-06-30 | 0001037646-26-000051 |
| 2026-07-30 | 16:32 ET | [8-K](/filings/0001037646-26-000049.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001037646-26-000049 |
| 2026-05-13 | 08:56 ET | [8-K](/filings/0001037646-26-000026.md) | 5.02 Departure or appointment of officers or directors | 0001037646-26-000026 |
| 2026-05-11 | 16:41 ET | [8-K](/filings/0001037646-26-000024.md) | 5.07 Shareholder vote results | 0001037646-26-000024 |
| 2026-05-08 | 11:42 ET | [10-Q](/filings/0001037646-26-000021.md) | Quarterly report, period 2026-03-31 | 0001037646-26-000021 |
| 2026-05-07 | 16:33 ET | [8-K](/filings/0001037646-26-000019.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001037646-26-000019 |
| 2026-03-18 | 08:30 ET | [DEF 14A](/filings/0001174947-26-000389.md) | Proxy statement, period 2026-05-07 | 0001174947-26-000389 |
| 2026-02-06 | 11:53 ET | [10-K](/filings/0001037646-26-000011.md) | Annual report, period 2025-12-31 | 0001037646-26-000011 |
| 2026-02-05 | 16:39 ET | [8-K](/filings/0001037646-26-000008.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001037646-26-000008 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001037646-26-000011.md), filed Feb 6, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/260ba660-2ddd-46d9-8b6c-925cab9a1e21)

## About the filer

- CIK: 1037646
- Tickers: MTD
- Exchange: NYSE
- SIC code: 3826 Laboratory Analytical Instruments
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.